C:\Program Files\Stnexp\Queries\10577047.str





```
chain nodes :
    13  14  15  16  17  18  19  20  21  23  24  26  27  28  41  43  56  57  58  59  60  61  62  63
    64  70
ring nodes :
    1  2  3  4  5  6  7  8  9  10  11  12  44  45  46  47  48  49  50  51  52  53  54  55
chain bonds :
    6-41  9-56  13-19  14-20  15-27  16-28  17-21  18-21  19-23  20-24  21-26  41-43  46-57  52-58
    56-59  57-60  58-61  59-62  60-63  61-64
ring bonds :
    1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  44-45  44-49  45-46  46-47
    47-48  48-49  50-51  50-55  51-52  52-53  53-54  54-55
exact/norm bonds :
    6-41  9-56  13-19  14-20  15-27  16-28  17-21  18-21  19-23  20-24  21-26  41-43  46-57  52-58
    56-59  57-60  58-61  59-62  60-63  61-64
normalized bonds :
    1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  44-45  44-49  45-46  46-47
    47-48  48-49  50-51  50-55  51-52  52-53  53-54  54-55
isolated ring systems :
    containing 1 : 7 : 44 : 50 :


G1:O,S

G2:N,[*1-*2],[*3-*4],[*5-*6],[*7-*8],[*9-*10]

G3:Cy,Ak

G4:[*11],[*12],[*13]

Match level :
    1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom  11:Atom
    12:Atom  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS  19:CLASS  20:CLASS
    21:CLASS  23:CLASS  24:CLASS  26:CLASS  27:CLASS  28:CLASS  41:CLASS  43:CLASS  44:Atom
    45:Atom  46:Atom  47:Atom  48:Atom  49:Atom  50:Atom  51:Atom  52:Atom  53:Atom  54:Atom
    55:Atom  56:CLASS  57:CLASS  58:CLASS  59:CLASS  60:CLASS  61:CLASS  62:CLASS  63:CLASS
    64:CLASS
```

70:CLASS 71:Atom

=>
Uploading C:\Program Files\Stnexp\Queries\10577047.str



chain nodes :
13 14 15 16 17 18 19 20 21 23 24 26 27 28 41 43 56 57 58 59 60
61 62 63 64 70
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 44 45 46 47 48 49 50 51 52 53 54
55
chain bonds :

```
6-41  9-56  13-19  14-20  15-27  16-28  17-21  18-21  19-23  20-24  21-26  41-43
46-57  52-58  56-59  57-60  58-61  59-62  60-63  61-64
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  44-45  44-49
45-46  46-47  47-48  48-49  50-51  50-55  51-52  52-53  53-54  54-55
exact/norm bonds :
6-41  9-56  13-19  14-20  15-27  16-28  17-21  18-21  19-23  20-24  21-26  41-43
46-57  52-58  56-59  57-60  58-61  59-62  60-63  61-64
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  44-45  44-49
45-46  46-47  47-48  48-49  50-51  50-55  51-52  52-53  53-54  54-55
isolated ring systems :
containing 1 : 7 : 44 : 50 :


G1:O,S

G2:N,[*1-*2],[*3-*4],[*5-*6],[*7-*8],[*9-*10]

G3:Cy,Ak

G4:[*11],[*12],[*13]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:CLASS  18:CLASS
19:CLASS  20:CLASS  21:CLASS  23:CLASS  24:CLASS  26:CLASS  27:CLASS  28:CLASS
41:CLASS  43:CLASS  44:Atom  45:Atom  46:Atom  47:Atom  48:Atom  49:Atom  50:Atom
51:Atom  52:Atom  53:Atom  54:Atom  55:Atom  56:CLASS  57:CLASS  58:CLASS  59:CLASS
 60:CLASS  61:CLASS  62:CLASS  63:CLASS  64:CLASS  70:CLASS  71:Atom



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 11:22:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -    41069 TO ITERATE

  4.9% PROCESSED     2000 ITERATIONS                                  9 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       809266 TO   833494
PROJECTED ANSWERS:            2881 TO     4511
```

```
L2             9 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 11:25:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   826351 TO ITERATE

 81.8% PROCESSED   675878 ITERATIONS                      2506 ANSWERS

 91.4% PROCESSED   755464 ITERATIONS                      2506 ANSWERS

 99.1% PROCESSED   818956 ITERATIONS                      2506 ANSWERS

100.0% PROCESSED   826351 ITERATIONS                      2506 ANSWERS
SEARCH TIME: 00.00.53

L3          2506 SEA SSS FUL L1

=> => s l3
L4            27 L3

=> d l4 1-27 bib,ab,hitstr
```

L4 ANSWER 1 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:296443 CAPLUS
DN 150:306672
TI Preparation of phenylaminopyrimidine derivatives and analogs as protein kinase inhibitors
IN Kamenecka, Theodore Mark; Jiang, Rong; Song, Xinyi; Lograsso, Philip; Cameron, Michael Darin
PA The Scripps Research Institute, USA
SO PCT Int. Appl., 278pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009032861	A1	20090312	WO 2008-US75151	20080903
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US 2007-969849P	P	20070904		

OS MARPAT 150:306672
AB Title compds. I [each Z independently = CH or N; each R1 independently = halo, CF3, (un)substituted alkyl, etc.; each R2 independently = halo, OCF3, NO2, etc.; or R1 and R2 that are attached to adjacent ring carbons are taken together with the ring atoms through which they are connected to form a heterocycloalkyl containing 1 or 2 oxygen atoms; R3 = H, Me, Et, CN, or halo; R4 = (un)substituted carbocyclic ring or heterocyclic ring containing 1 to 4 heteroatoms; m and n independently = 0 to 2 provided that their sum is 0 to 2; with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase inhibitors. Thus, e.g., II was prepared by coupling of 4-bromo-2-fluorobenzonitrile with bis(pinacolato)diboron followed by coupling with 2,4-dichloropyrimidine and coupling with 4-(3-methyl-1H-1,2,4-triazol-1-yl)aniline (preparation given). Select I were evaluated in JNK inhibition assays and demonstrated IC50 values of ≤10 μM. I were disclosed as therapeutic agents that are useful as inhibitors of protein kinases, especially c-Jun N-terminal kinases (JNK), for use in treating conditions responsive to the inhibition of the JNK pathway.
IT 1128097-21-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylaminopyrimidine derivs. and analogs as protein kinase inhibitors)
RN 1128097-21-1 CAPLUS
CN 2-Pyrimidinamine, N-[4-(3-methyl-1H-1,2,4-triazol-1-yl)phenyl]-4-[3-(4-morpholinyl)-5-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:239210 CAPLUS
DN 150:283069
TI Preparation of 2-heteroarylaminopyrimidine derivatives as protein kinase inhibitors
IN Chianelli, Donatella; Molteni, Valentina; Li, Xiaolin; Liu, Xiaodong; Nabakka, Juliet; Loren, Jon
PA IRM LLC, Bermuda
SO PCT Int. Appl., 80pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009026204	A1	20090226	WO 2008-US73438	20080818

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2007-957240P P 20070822
OS MARPAT 150:283069
AB Title compds. I [R = H, alkyl; R1 = alkyl, alkenyl, alkynyl; R2 = substituted 6-membered nitrogen heterocycle containing up to 4 nitrogen atoms; Ar = (un)substituted (hetero)aryl, with provisions], and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase inhibitors. For example, compound II was prepared via amidation of 5-[5-(4-methoxyphenyl)pyrimidin-2-ylamino]pyridine-2-carboxylic acid (preparation given) with N-BOC piperazine, followed by BOC deprotection. I demonstrated IC50 values in the range of 10 nM to 2μM in kinase activity assays with fibroblast growth factor receptor (FGFR3). The invention is also directed to methods of treating, ameliorating, or preventing conditions associated with abnormal or deregulated protein kinase activity, such as asthma, atopic dermatitis, urticaria, irritable bowel syndrome, or fibrosis.
IT 1123178-00-6P 1123178-03-9P 1123178-04-0P
1123178-05-1P 1123178-06-2P 1123178-07-3P
1123178-08-4P 1123178-09-5P 1123178-10-8P
1123178-11-9P 1123178-12-0P 1123178-13-1P
1123178-14-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (heteroarylamino)pyrimidine derivs. as protein kinase inhibitors)
RN 1123178-00-6 CAPLUS
CN Methanone, [5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-3-pyridinyl]-1-piperazinyl- (CA INDEX NAME)



RN 1123178-03-9 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methyl-3-pyridinyl]tetrahydro- (CA INDEX NAME)



RN 1123178-04-0 CAPLUS
CN 3-Piperidinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methyl-3-pyridinyl]-1-ethyl-6-oxo- (CA INDEX NAME)



RN 1123178-05-1 CAPLUS
CN 4-Piperidinecarboxamide, 1-cyclopropyl-N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methyl-3-pyridinyl]-2-oxo- (CA INDEX NAME)



RN 1123178-06-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-pyridinyl]ethyl]- (CA INDEX NAME)



RN 1123178-07-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-4-methyl-2-pyridinyl]ethyl]- (CA INDEX NAME)



RN 1123178-08-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methyl-3-pyridinyl]ethyl]- (CA INDEX NAME)



RN 1123178-09-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-3-pyridinyl]ethyl]- (CA INDEX NAME)



RN 1123178-10-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-pyridinyl]methyl]- (CA INDEX NAME)



RN 1123178-11-9 CAPLUS
CN Ethanone, 2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-pyridinyl]-1-(4-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 1123178-12-0 CAPLUS
CN 1-Propanone, 2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-pyridinyl]-3-hydroxy-1-(4-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 1123178-13-1 CAPLUS
CN 1-Propanone, 2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-pyridinyl]-1-(4-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 1123178-14-2 CAPLUS
CN 2-Pyridineacetamide, 5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-N-(2-hydroxypropyl)- (CA INDEX NAME)



IT 1123178-24-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (heteroarylamino)pyrimidine derivs. as protein kinase inhibitors)
RN 1123178-24-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:238950 CAPLUS
DN 150:283067
TI Preparation of 5-(4-(haloalkoxy)phenyl)pyrimidine-2-amine compounds as protein kinase inhibitors
IN Molteni, Valentina; Li, Xiaolin; Liu, Xiaodong; Chianelli, Donatella; Nabakka, Juliet; Loren, Jon; You, Shuli
PA IRM LLC, Bermuda
SO PCT Int. Appl., 137pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2009026276	A1	20090226	WO 2008-US73573	20080819
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US 2007-957260P	P	20070822		

OS MARPAT 150:283067
AB Title compds. I [R1 = haloalkoxy having 1-6 F atoms; R2 = substituted phenyl], and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase inhibitors. For example, compound II was prepared via Suzuki coupling of (5-bromopyrimidin-2-yl)-[4-(2-diethylaminoethoxy)phenyl]amine (preparation given) with 4-(trifluoromethoxy)phenylboronic acid. I demonstrated IC50 values in the range of 10 nM to 2 μM in kinase activity assays with fibroblast growth factor receptor (FGFR3). The invention is also directed to methods of treating, ameliorating, or preventing conditions associated with abnormal or deregulated kinase activity, such as asthma, atopic dermatitis, urticaria, irritable bowel syndrome, or fibrosis.
IT 1123512-96-8P 1123512-99-1P 1123513-90-5P
1123513-92-7P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ((haloalkoxy)phenyl)pyrimidinylamine compds. as protein kinase inhibitors)
RN 1123512-96-8 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-(4-hydroxy-1-piperidinyl)-, (2R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 1123512-99-1 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-(4-hydroxy-1-piperidinyl)-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-90-5 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-(4-methyl-1-piperazinyl)-, (2R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-92-7 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-(4-methyl-1-piperazinyl)-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



IT 1123513-94-9P 1123514-14-6P 1123514-21-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of ((haloalkoxy)phenyl)pyrimidinylamine compds. as protein kinase inhibitors)
RN 1123513-94-9 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-[3-(trifluoromethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 1123514-14-6 CAPLUS
CN 4,7-Diazaspiro[2.5]octane-7-carboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 1123514-21-5 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-3-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123514-20-4
CMF C24 H23 F5 N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT

1123512-27-5P	1123512-30-0P	1123512-33-3P
1123512-36-6P	1123512-40-2P	1123512-43-5P
1123512-46-8P	1123512-47-9P	1123512-52-6P
1123512-55-9P	1123512-59-3P	1123512-62-8P
1123512-65-1P	1123512-68-4P	1123512-69-5P
1123512-74-2P	1123512-75-3P	1123512-80-0P
1123512-83-3P	1123512-86-6P	1123512-87-7P
1123512-93-5P	1123513-02-9P	1123513-03-0P
1123513-08-5P	1123513-09-6P	1123513-14-3P
1123513-17-6P	1123513-20-1P	1123513-23-4P
1123513-26-7P	1123513-29-0P	1123513-32-5P
1123513-35-8P	1123513-38-1P	1123513-41-6P
1123513-44-9P	1123513-47-2P	1123513-50-7P
1123513-53-0P	1123513-56-3P	1123513-59-6P
1123513-62-1P	1123513-65-4P	1123513-68-7P
1123513-71-2P	1123513-74-5P	1123513-76-7P
1123513-78-9P	1123513-80-3P	1123513-82-5P
1123513-84-7P	1123513-86-9P	1123513-88-1P
1123513-96-1P	1123513-98-3P	1123513-99-4P
1123514-02-2P	1123514-04-4P	1123514-06-6P
1123514-08-8P	1123514-10-2P	1123514-12-4P
1123514-16-8P	1123514-18-0P	1123514-20-4P
1123514-25-9P	1123514-26-0P	1123514-29-3P
1123514-31-7P	1123514-33-9P	1123514-35-1P
1123514-37-3P	1123514-39-5P	1123514-41-9P

1123514-43-1P 1123514-44-2P 1123514-47-5P
1123514-49-7P 1123514-51-1P 1123514-53-3P
1123514-55-5P 1123514-58-8P 1123514-60-2P
1123514-62-4P 1123514-64-6P 1123514-66-8P
1123514-68-0P 1123514-70-4P 1123514-72-6P
1123514-74-8P 1123514-76-0P 1123514-79-3P
1123514-81-7P 1123514-83-9P 1123514-85-1P
1123514-87-3P 1123514-89-5P 1123514-91-9P
1123514-93-1P 1123514-95-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ((haloalkoxy)phenyl)pyrimidinylamine compds. as protein kinase inhibitors)

RN 1123512-27-5 CAPLUS
CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-5-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1123512-30-0 CAPLUS
CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-5-[4-(difluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1123512-33-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenoxy]ethyl]- (CA INDEX NAME)



RN 1123512-36-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]methyl]- (CA INDEX NAME)



RN 1123512-40-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[4-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]methyl]- (CA INDEX NAME)



RN 1123512-43-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]ethyl]- (CA INDEX NAME)



RN 1123512-46-8 CAPLUS
CN 2-Piperidinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-1-methyl- (CA INDEX NAME)



RN 1123512-47-9 CAPLUS
CN 2-Piperidinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-1-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123512-46-8

CMF C25 H27 F2 N5 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 1123512-52-6 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-, (1S,2R,5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123512-55-9 CAPLUS
CN 2-Piperidinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 1123512-59-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-5-oxo-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123512-62-8 CAPLUS
CN 3-Piperidinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-6-oxo- (CA INDEX NAME)



RN 1123512-65-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-6-fluoro- (CA INDEX NAME)



RN 1123512-68-4 CAPLUS
CN 1H-Imidazole-5-carboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 1123512-69-5 CAPLUS
CN 1H-Imidazole-5-carboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123512-68-4
CMF C22 H18 F2 N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 1123512-74-2 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-methyl-5-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-5-oxo-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123512-75-3 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-methyl-5-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-5-oxo-, (2S)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123512-74-2
CMF C23 H20 F3 N5 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 1123512-80-0 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-cyclopropyl-N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-5-oxo- (CA INDEX NAME)



RN 1123512-83-3 CAPLUS
CN 3-Piperidinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-1-ethyl-6-oxo- (CA INDEX NAME)



RN 1123512-86-6 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-(2-fluoroethyl)-α-(hydroxymethyl)- (CA INDEX NAME)



RN 1123512-87-7 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-(2-fluoroethyl)-α-(hydroxymethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123512-86-6
CMF C22 H21 F3 N4 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 1123512-93-5 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-(4-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 1123513-02-9 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-N-[(2R)-2-hydroxypropyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-03-0 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-N-[(2R)-2-hydroxypropyl]-, (αR)-,

2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123513-02-9
CMF C23 H24 F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 1123513-08-5 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-N-[(2R)-2-hydroxypropyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-09-6 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-N-[(2R)-2-hydroxypropyl]-, (αS)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123513-08-5
CMF C23 H24 F2 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 1123513-14-3 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-N-[(2S)-2-hydroxypropyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-17-6 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-N-[(2S)-2-hydroxypropyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-20-1 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-N-[(2S)-2-hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-23-4 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-(trans-4-hydroxycyclohexyl)-α-(hydroxymethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 1123513-26-7 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-(trans-4-hydroxycyclohexyl)-α-(hydroxymethyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-29-0 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-(trans-4-hydroxycyclohexyl)-α-(hydroxymethyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-32-5 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-(cis-4-hydroxycyclohexyl)-α-(hydroxymethyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-35-8 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-(cis-4-hydroxycyclohexyl)-α-(hydroxymethyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-38-1 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-(cis-4-hydroxycyclohexyl)-α-(hydroxymethyl)- (CA INDEX NAME)

Relative stereochemistry.



RN 1123513-41-6 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-(3-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 1123513-44-9 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-[(3S)-3-hydroxy-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-47-2 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-[(3S)-3-hydroxy-1-piperidinyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-50-7 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-[(3S)-3-hydroxy-1-piperidinyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-53-0 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-[(3R)-3-hydroxy-1-piperidinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-56-3 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-[(3R)-3-hydroxy-1-piperidinyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-59-6 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-[(3R)-3-hydroxy-1-piperidinyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-62-1 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-(2-hydroxycyclopentyl)-α-(hydroxymethyl)- (CA INDEX NAME)



RN 1123513-65-4 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-[(1R,2R)-2-hydroxycyclopentyl]-α-(hydroxymethyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-68-7 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-[(1S,2R)-2-hydroxycyclopentyl]-α-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-71-2 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]-α-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-74-5 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-[(1R,2R)-2-hydroxycyclopentyl]-α-(hydroxymethyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-76-7 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]-α-(hydroxymethyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-78-9 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-[(1S,2R)-2-hydroxycyclopentyl]-α-(hydroxymethyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-80-3 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-[(1S,2S)-2-hydroxycyclopentyl]-α-(hydroxymethyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-82-5 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-[(1S,2R)-2-hydroxycyclopentyl]-α-(hydroxymethyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123513-84-7 CAPLUS
CN 2-Propen-1-one, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-1-(4-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 1123513-86-9 CAPLUS
CN Ethanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-1-(4-hydroxy-1-piperidinyl)- (CA INDEX NAME)



RN 1123513-88-1 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 1123513-96-1 CAPLUS
CN 1-Propanone, 2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-3-hydroxy-1-[4-methyl-3-(trifluoromethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 1123513-98-3 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 1123513-99-4 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123513-98-3
CMF C25 H26 F2 N6 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 1123514-02-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-4-methyl- (CA INDEX NAME)



RN 1123514-04-4 CAPLUS

CN 1-Piperazinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-4-(methylsulfonyl)- (CA INDEX NAME)



RN 1123514-06-6 CAPLUS
CN 1-Piperazinecarboxamide, 4-acetyl-N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 1123514-08-8 CAPLUS
CN Urea, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-N'-(1,3-dimethyl-1H-pyrazol-5-yl)- (CA INDEX NAME)



RN 1123514-10-2 CAPLUS
CN 4-Morpholinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 1123514-12-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-

pyrimidinyl]amino]-2-methylphenyl]-4-(2-hydroxyethyl)- (CA INDEX NAME)



RN 1123514-16-8 CAPLUS
CN 4,7-Diazaspiro[2.5]octane-7-carboxamide,
N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-
4-methyl- (CA INDEX NAME)



RN 1123514-18-0 CAPLUS
CN 4,7-Diazaspiro[2.5]octane-7-carboxamide,
N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-
4-(2-hydroxyethyl)- (CA INDEX NAME)



RN 1123514-20-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-3-(trifluoromethyl)- (CA INDEX NAME)



RN 1123514-25-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-4-methyl-3-(trifluoromethyl)- (CA INDEX NAME)



RN 1123514-26-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-4-methyl-3-(trifluoromethyl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123514-25-9
CMF C25 H25 F5 N6 O2



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 1123514-29-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-4-methyl-3-oxo- (CA INDEX NAME)



RN 1123514-31-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-4-(2-hydroxyethyl)-3-oxo- (CA INDEX NAME)



RN 1123514-33-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenoxy]ethyl]- (CA INDEX NAME)



RN 1123514-35-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]ethyl]- (CA INDEX NAME)



RN 1123514-37-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]methyl]- (CA INDEX NAME)



RN 1123514-39-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-fluorophenoxy]ethyl]- (CA INDEX NAME)



RN 1123514-41-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]ethyl]- (CA INDEX NAME)



RN 1123514-43-1 CAPLUS
CN 2-Piperazinone, 4-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]benzoyl]-1-methyl- (CA INDEX NAME)



RN 1123514-44-2 CAPLUS
CN 2-Piperazinone, 4-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]benzoyl]-1-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 1123514-43-1
CMF C23 H21 F2 N5 O3



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 1123514-47-5 CAPLUS
CN 2-Piperazinone, 4-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]benzoyl]-1-(2-hydroxyethyl)- (CA INDEX NAME)



RN 1123514-49-7 CAPLUS
CN 2-Piperazinone, 4-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]benzoyl]- (CA INDEX NAME)



RN 1123514-51-1 CAPLUS
CN Methanone, [4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl][3-(trifluoromethyl)-1-piperazinyl]- (CA INDEX NAME)



RN 1123514-53-3 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]ethyl]-, ethyl ester (CA INDEX NAME)



RN 1123514-55-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-hydroxyphenyl]ethyl]- (CA INDEX NAME)



RN 1123514-58-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[1-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]ethyl]- (CA INDEX NAME)



RN 1123514-60-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]methyl]- (CA INDEX NAME)



RN 1123514-62-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-fluorophenyl]methyl]- (CA INDEX NAME)



RN 1123514-64-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-hydroxyphenyl]methyl]- (CA INDEX NAME)



RN 1123514-66-8 CAPLUS
CN 2-Piperazinone, 4-[3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]benzoyl]-1-(4-piperidinyl)- (CA INDEX NAME)



RN 1123514-68-0 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[4-[3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]benzoyl]-2-oxo-1-piperazinyl]-, 1-methylethyl ester (CA INDEX NAME)



RN 1123514-70-4 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[1-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-2-hydroxyethyl]tetrahydro- (CA INDEX NAME)



RN 1123514-72-6 CAPLUS
CN 3-Piperidinecarboxamide, N-[1-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-2-hydroxyethyl]-1-ethyl-6-oxo- (CA INDEX NAME)



RN 1123514-74-8 CAPLUS
CN 3-Pyrrolidinecarboxamide, 1-cyclopropyl-N-[1-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-2-hydroxyethyl]-5-oxo- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1123514-76-0 CAPLUS
CN 4-Isoxazolecarboxamide, N-[1-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-2-hydroxyethyl]-3,5-dimethyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1123514-79-3 CAPLUS
CN 5-Isoxazolecarboxamide, N-[1-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-2-hydroxyethyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1123514-81-7 CAPLUS
CN 5-Isoxazoleacetamide, N-[1-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-2-hydroxyethyl]-3-methyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1123514-83-9 CAPLUS
CN 2H-Pyran-4-acetamide, N-[1-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-2-hydroxyethyl]tetrahydro- (CA INDEX NAME)



RN 1123514-85-1 CAPLUS
CN 1,3-Piperidinedicarboxamide, N3-[1-[4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-2-hydroxyethyl]- (CA INDEX NAME)



RN 1123514-87-3 CAPLUS
CN 3-Azabicyclo[3.1.0]hexane-2-carboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]- (CA INDEX NAME)



RN 1123514-89-5 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-5-oxo- (CA INDEX NAME)



RN 1123514-91-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[2-methyl-5-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]-5-oxo- (CA INDEX NAME)



RN 1123514-93-1 CAPLUS

CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-N-(2-hydroxypropyl)- (CA INDEX NAME)



RN 1123514-95-3 CAPLUS
CN Benzeneacetamide, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-N-(4-hydroxycyclohexyl)-α-(hydroxymethyl)- (CA INDEX NAME)



IT 1123515-96-7P 1123515-98-9P 1123516-01-7P
1123516-04-0P 1123516-06-2P 1123516-08-4P
1123516-10-8P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ((haloalkoxy)phenyl)pyrimidinylamine compds. as protein kinase inhibitors)
RN 1123515-96-7 CAPLUS
CN Benzeneacetic acid, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123515-98-9 CAPLUS
CN Benzeneacetic acid, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1123516-01-7 CAPLUS
CN 4,7-Diazaspiro[2.5]octane-7-carboxamide, N-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]-4-(phenylmethyl)- (CA INDEX NAME)



RN 1123516-04-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]amino]carbonyl]-2-(trifluoromethyl)-, ethyl ester (CA INDEX NAME)



RN 1123516-06-2 CAPLUS
CN Ethanol, 2-[3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenoxy]-, 1-methanesulfonate (CA INDEX NAME)



RN 1123516-08-4 CAPLUS
CN Benzeneethanol, 3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-, 1-methanesulfonate (CA INDEX NAME)



RN 1123516-10-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]methyl]-, methyl ester (CA INDEX NAME)



IT 1123515-34-3P 1123515-38-7P 1123515-40-1P
1123515-42-3P 1123515-44-5P 1123515-47-8P
1123515-49-0P 1123515-57-0P 1123515-59-2P
1123515-61-6P 1123515-63-8P 1123515-65-0P
1123515-67-2P 1123515-69-4P 1123515-81-0P
1123515-83-2P 1123515-85-4P 1123515-87-6P
1123515-92-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ((haloalkoxy)phenyl)pyrimidinylamine compds. as protein kinase inhibitors)
RN 1123515-34-3 CAPLUS
CN Benzeneacetic acid, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)- (CA INDEX NAME)



RN 1123515-38-7 CAPLUS
CN 2-Pyrimidinamine, 5-[4-(difluoromethoxy)phenyl]-N-(4-methyl-3-nitrophenyl)- (CA INDEX NAME)



RN 1123515-40-1 CAPLUS
CN 1,3-Benzenediamine, N1-[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]-4-methyl- (CA INDEX NAME)



RN 1123515-42-3 CAPLUS
CN 2-Pyrimidinamine, N-(4-methyl-3-nitrophenyl)-5-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



RN 1123515-44-5 CAPLUS
CN 1,3-Benzenediamine, 4-methyl-N1-[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 1123515-47-8 CAPLUS
CN Benzeneacetic acid, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 1123515-49-0 CAPLUS
CN Benzeneacetic acid, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-α-(hydroxymethyl)-, ethyl ester (CA INDEX NAME)



RN 1123515-57-0 CAPLUS
CN Phenol, 3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1123515-59-2 CAPLUS
CN Ethanol, 2-[3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenoxy]- (CA INDEX NAME)



RN 1123515-61-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenoxy]ethyl]-, ethyl ester (CA INDEX NAME)



RN 1123515-63-8 CAPLUS
CN Benzeneethanol, 3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1123515-65-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]ethyl]-, ethyl ester (CA INDEX NAME)



RN 1123515-67-2 CAPLUS
CN Benzenemethanol, 3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 1123515-69-4 CAPLUS
CN Benzenemethanol, 3-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-,

1-methanesulfonate (CA INDEX NAME)



RN 1123515-81-0 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-fluorophenoxy]ethyl]-, methyl ester (CA INDEX NAME)



RN 1123515-83-2 CAPLUS
CN Benzeneethanol, 5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methyl- (CA INDEX NAME)



RN 1123515-85-4 CAPLUS
CN Benzeneethanol, 5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methyl-, 1-methanesulfonate (CA INDEX NAME)



RN 1123515-87-6 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[5-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]-2-methylphenyl]ethyl]-, ethyl ester (CA INDEX NAME)



RN 1123515-92-3 CAPLUS
CN Benzoic acid, 4-[[5-[4-(difluoromethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1127907 CAPLUS
DN 149:402373
TI (Phenylamino)pyrimidine derivatives as protein kinases inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
IN Burns, Christopher John; Donohue, Andrew Craig; Feutrill, John Thomas; Ngygen, Thao Lien Thi; Wilks, Andrew Frederick; Zeng, Jun
PA Cytopia Research Pty Ltd, Australia
SO PCT Int. Appl., 104pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008109943	A1	20080918	WO 2008-AU339	20080312
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2007-894264P	P	20070312		
US 2007-16252P	P	20071221		

OS MARPAT 149:402373
AB The invention relates to (phenylamino)pyrimidine derivs. of formula I, which are inhibitors of protein kinases including JAK kinases. In particular, the compds. are selective for JAK2 kinases. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunol. and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases. Compds. of formula I wherein Q and Z are independently N and CR1; R1 is H, halo, R2, OR2, OH, R4, OR4, CN, CF3, (CH2)1-3-N(R2)2, NO2, etc.; R2 is (un)substituted C1-4 alkyl and (un)substituted C1-4 alkylene where up to two carbon atoms can be optionally replaced with CO, NH and derivs., CONH and derivs., S, SO2 and O; R4 is NH2 and derivs., (un)substituted (thio)morpholino, (un)substituted thiomorpholino-1-oxide, etc.; R6-R10 are independently H, RxCN, halo, (un)substituted C1-4 alkyl, OR1, CO2R1, N(R1)2, NO2, CON(R1)2, etc.; Rx is absent, (un)substituted C1-6 alkylene where up to two carbon atoms can be optionally replaced with CO, NSO2R1, CONH and derivs., S, SO2 and O; R11 is H, halo, (un)substituted C1-4 alkyl, OR2, CO2R2, CN, CON(R1)2 and CF3; and their enantiomers, prodrugs and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepd.via Suzuki coupling of 4-(ethoxycarbonyl)phenylboronic acid with 2,4-dichloropyrimidine followed by amination with 4-morpholinoaniline, hydrolysis and amidation with aminoacetonitrile. All the invention compds. were evaluated for their protein kinases inhibitory activity. From the assay, it was determined that II exhibited an IC50 value of < 5 μM against JAK2.

IT 1056635-77-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of (phenylamino)pyrimidine derivs. as protein kinase inhibitors useful in treatment of diseases)
RN 1056635-77-8 CAPLUS
CN Acetamide, 2-cyano-N-[4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:1006418 CAPLUS
DN 149:288795
TI New phenyl(4-phenylpyrimidin-2-yl)amine derivatives, their preparation as IKK inhibitors and their pharmaceutical compositions
IN Bouaboula, Monsif; Casellas, Pierre; Dudal, Sherri; Floutard, Regine; Mendez-Perez, Maria; Nguefack, Jean-Flaubert; Olsen, Jacob-Alsboek; Tonnerre, Bernard; Wagnon, Jean
PA Sanofi-Aventis, Fr.
SO PCT Int. Appl., 142pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008099074	A1	20080821	WO 2008-FR3	20080102
	W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	FR 2911139	A1	20080711	FR 2007-65	20070105
PRAI	FR 2007-65	A	20070105		

OS MARPAT 149:288795
AB The invention is related to the preparation of phenyl(4-phenylpyrimidin-2-yl)amines I [R, R5 = independently H, halo; R2-4 = independently H, halo, CN, CONH2, alkyl, etc.; Z = CO, SO2; NDW is defined as follows: (a) either W = ring(Y) and D = H, (un)substituted cycloalkyl, alk(en/yn)yl; ring(Y) = 4-10 membered saturated or partially saturated mono- or bicyclyl with Y = O, S, SO, SO2, NH and derivs., CO, etc., e.g. pyrrolidinyl, dioxothiophenyl, and tetrahydropyranyl, with proviso; (b) or NWD = 4-7 saturated membered ring substituted by 2 substituents on the same carbon and optionally containing a C bridge comprising 1-3 C's], their isomers, and their mineral and organic acid addition salts as IKK inhibitors. For instance, S-methylation of 2-thiopyrimidin-4-ol with Me iodide, reaction of the methylsulfanyl intermediate with aniline, chlorination of pyrimidinol with POCl3, chlorosulfonation of the aniline intermediate with chlorosulfonic acid, reaction of the sulfonyl chloride with 4-[methyl(tert-butoxycarbonyl)amino]piperidine, Suzuki coupling of the chloride with 4-fluorophenylboronic acid and cleavage of the tert-butoxycarbonyl group gave pyrimidine II (m.p. = 202.9°). I inhibited IKK1 and IKK2 with an IC50 <10 μM. Pyrimidines I displayed IC50's <10 μM against proliferation of breast, prostate, colon, and lung cancer, glioblastoma and leukemia cell lines. Thus, I and their pharmaceutical compns., are useful for treating inflammation (no data), diabetes (no data), and neoplasm (data).
IT 1049105-11-4P, 4-[(Pyrrolidin-1-yl)methyl]-1-[[4-[[4-(4-trifluoromethoxyphenyl)pyrimidin-2-yl]amino]phenyl]sulfonyl]piperidin-4-ol

1049105-24-9P 1049105-35-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenyl(4-phenylpyrimidin-2-yl)amines as IKK inhibitors for treating inflammation, diabetes, and neoplasm)

RN 1049105-11-4 CAPLUS

CN 4-Piperidinol, 4-(1-pyrrolidinylmethyl)-1-[[4-[[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]phenyl]sulfonyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 1049105-24-9 CAPLUS

CN 2-Pyrimidinamine, N-[4-[[4-[(R)-amino(4-fluorophenyl)methyl]-1-piperidinyl]sulfonyl]phenyl]-4-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1049105-35-2 CAPLUS
CN 2-Pyrimidinamine, N-[4-[[4-[(S)-amino(4-fluorophenyl)methyl]-1-piperidinyl]sulfonyl]phenyl]-4-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:1274706 CAPLUS
DN 147:522221
TI Preparation of carboxylic acid derivatives containing thiazole moiety for the treatment of diabetic hyperlipidemia
IN Tamakawa, Hiroki; Iizuka, Hiroyuki; Sakai, Kaoru
PA Mitsubishi Pharma Corporation, Japan
SO PCT Int. Appl., 517pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007126043	A1	20071108	WO 2007-JP59151	20070427
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	JP 2006-122804	A	20060427		

OS MARPAT 147:522221
AB Title compds. I [R1, R2 = H or alkyl; R1 and R2 may combine to form a cycloalkyl group; R3 = H or alkyl; R4 = H, alkyl or aryl; n = 1-5; Y = oxygen, sulfur atom, -NR5-, etc.; R5 = H, alkyl, cycloalkyl-alkyl, etc.; Z = cycloalkyl, aryl, arylalkyl, etc.] or pharmaceutically acceptable salts, hydrates or solvates thereof were prepared For example, a multi-step synthesis of compound II, starting from 4-chloro-3-oxobutanoic acid Et ester, was given. Compds. herein were tested for plasma triglyceride (TG) decreasing effect, free fatty acid (FFA) decreasing effect and serum HDL cholesterol increasing effect.
IT 886529-09-5P 886529-11-9P 886529-18-6P
886529-19-7P 886529-20-0P 886529-21-1P
886529-44-8P 886529-45-9P 886529-63-1P
886529-64-2P 886530-11-6P 886535-99-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxylic acid derivs. containing thiazole moiety for treatment
of diabetic hyperlipidemia)
RN 886529-09-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 886529-11-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[methyl[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 886529-18-6 CAPLUS
CN Propanoic acid, 2-[[4-[2-[ethyl[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-2-methyl- (CA INDEX NAME)



RN 886529-19-7 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[(1-methylethyl)[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 886529-20-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 886529-21-1 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[5-[3-(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 886529-44-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[5-[3-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 886529-45-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[methyl[5-[3-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 886529-63-1 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-methyl-5-[2-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



RN 886529-64-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-methyl-5-[2-[methyl[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



RN 886530-11-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)





RN 886535-99-5 CAPLUS
CN Acetic acid, 2-[[4-[2-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)

IT 886529-08-4P 886529-10-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carboxylic acid derivs. containing thiazole moiety for treatment
of diabetic hyperlipidemia)

RN 886529-08-4 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[2-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 886529-10-8 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[2-[methyl[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:1253175 CAPLUS
DN 146:27856
TI Preparation of 4-amino pyrimidine compounds as modulators of ATP-binding cassette transporters for treating disease
IN Hadida Ruah, Sara S.; Hazlewood, Anna R.; Grootenhuis, Peter D. J.; Singh, Ashvani K.; Cleveland, Thomas; Van Goor, Frederick F.
PA Vertex Pharmaceuticals Incorporated, USA
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006127588	A2	20061130	WO 2006-US19712	20060522
	WO 2006127588	A3	20070726		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2006251624	A1	20061130	AU 2006-251624	20060522
	CA 2609392	A1	20061130	CA 2006-2609392	20060522
	US 20070105833	A1	20070510	US 2006-438636	20060522
	EP 1891018	A2	20080227	EP 2006-770825	20060522
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	JP 2008542279	T	20081127	JP 2008-513583	20060522
	IN 2007KN04531	A	20080208	IN 2007-KN4531	20071123
	CN 101223146	A	20080716	CN 2006-80025869	20080115
PRAI	US 2005-683982P	P	20050524		
	WO 2006-US19712	W	20060522		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 146:27856; MARPAT 146:27856
AB 4-Amido-pyrimidine compds., derivs. and compns. thereof, and synthetic methods described are useful for modulating ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. The compds. of the invention have general formula I (wherein Ra = H, (un)substituted aliphatic, (un)substituted aryl, etc.; Rb = (un)substituted aliphatic, (un)substituted aryl, etc.; Rc = H, (un)substituted heterocycloaliph., (un)substituted cycloaliph., or aliphatic; Rd = H, (un)substituted aliphatic or aryl, etc.; A = (un)substituted aryl or heteroaryl). For example, 2-(dimethylamino)-6-(2-methoxyphenyl)pyrimidine-4-carboxamide was prepared in 5 steps via dioxobutanoic acid, methylthio, and sulfinyl intermediates.
IT 915965-79-6P, 2-Diethylamino-6-[3-

(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide 915967-01-0P
, 2-Diethylamino-6-[4-(trifluoromethoxy)phenyl]pyrimidine-4-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of 4-amino pyrimidine compds. as modulators of
ATP-binding cassette transporters for treating disease)

RN 915965-79-6 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[3-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)



RN 915967-01-0 CAPLUS
CN 4-Pyrimidinecarboxamide, 2-(diethylamino)-6-[4-(trifluoromethoxy)phenyl]-
(CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 8 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:1089222 CAPLUS
DN 145:438632
TI Preparation of phenylheteroaryl compounds, herbicides containing them, and their usage
IN Takizawa, Eiji; Kumata, Shuji; Kiyokawa, Takahiro
PA Nihon Nohyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 29pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2006282552	A	20061019	JP 2005-102985	20050331
PRAI JP 2005-102985		20050331		

OS MARPAT 145:438632
AB The compds. I [R1 = H, C1-8 (halo)alkyl, C1-8 (halo)alkoxy, (un)substituted Ph, etc.; R2 = H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 (halo)alkylsulfonyl, etc.; R3 = halo, C1-8 (halo)alkyl, C1-8 alkoxycarbonyl, SiMe3, cyano, NO2, etc.; 2 neighboring R3s may be bonded together to form OCF2CF2O, OCH2O, OCH2CH2O; G = CO, CS, CR62 (R6 = H, cyano, C1-8 alkyl: R6s may be bonded together to form a C, N, O, or S-containing 3-6-membered ring; X = direct bond, CO, CS, SOq (q = 1, 2); Y = CR7 R7 = H, halo, cyano, NO2, OH, CO2H, SF5, C1-8 alkylamino, etc.), N→Op (p = 0, 1), wherein ≥2 of Y = N→Op; t = 0-2; m = 1-5] or their salts are claimed. Also claimed are herbicides containing I or their salts and usage of herbicides to apply them to soils or plant. Thus, a EtOAc solution of [4-methyl-6-(3-trifluoromethoxyphenyl)pyrimidin-2-yl]methylamine and Et3N was treated with cyclopropanecarbonyl chloride at 0-4° for 30 min to give 83% N-[[4-methyl-6-(3-trifluoromethoxyphenyl)pyrimidin-2-yl]methyl]cyclopropanecarboxamide. This showed ≥90% inhibition at 1000 g a.i./ha on growth of Scirpus hotarui, Monochoria vaginalis, Lindernia pyxidaria, etc.
IT 912850-79-4P
RL: AGR (Agricultural use); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylheteroaryl compds. as herbicides)
RN 912850-79-4 CAPLUS
CN 2-Pyrimidinecarboxamide, N-(4-fluorophenyl)-4-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



IT 912850-78-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenylheteroaryl compds. as herbicides)
RN 912850-78-3 CAPLUS
CN 2-Pyrimidinamine, N,4-dimethyl-6-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 9 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:436703 CAPLUS
DN 144:468151
TI Preparation of carboxylic acid derivatives containing thiazole moiety as PPARα agonists
IN Tozawa, Takashi; Tsuruta, Osamu; Kitajima, Hiroshi; Aoki, Yoshiyuki; Ando, Naoko; Tamakawa, Hiroki
PA Mitsubishi Pharma Corporation, Japan
SO PCT Int. Appl., 512 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006049232	A1	20060511	WO 2005-JP20262	20051104
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005301626	A1	20060511	AU 2005-301626	20051104
	CA 2587023	A1	20060511	CA 2005-2587023	20051104
	EP 1816128	A1	20070808	EP 2005-800453	20051104
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101068797	A	20071107	CN 2005-80037890	20051104
	BR 2005017065	A	20080930	BR 2005-17065	20051104
	KR 2007085687	A	20070827	KR 2007-712516	20070601
	IN 2007CN02394	A	20070907	IN 2007-CN2394	20070604
	US 20080167307	A1	20080710	US 2007-667006	20071115
PRAI	JP 2004-321347	A	20041104		
	WO 2005-JP20262	W	20051104		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 144:468151
AB Title compds. I [R1, R2 = H, alkyl; R1 and R2 may combine to form cycloalkyl; R3 = H, alkyl; R4 = H, alkyl, aryl; n = 1-5; Y = -O-, -S-, -NR5-, etc; R5 = H, alkyl, cycloalylalkyl, etc.; Z = cycloalkyl, aryl, arylalkyl, etc.] and their pharmaceutically acceptable salts were prepared For example, DIAD mediated alkylation of 2-[[4-(2-hydroxyethyl)-1,3-thiazol-2-yl]thio]-2-methylpropionic acid tert-Bu ester, e.g., prepared from 4-chloro-3-oxobutanoic acid Et ester in 4 steps, with 4'-fluorobiphenyl-4-ol followed by treatment with trifluoroacetic acid afforded compound II. In PPARα transcription activation assays, the EC50 value of compound II was 10.4 nmol/L. Compds. I are claimed useful for the treatment of hyperlipidemia, arteriosclerosis, etc.
IT 886529-08-4P 886529-10-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of carboxylic acid derivs. containing thiazole moiety as PPARα agonists for treatment of hyperlipidemia and arteriosclerosis)

RN 886529-08-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 886529-10-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[methyl[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 886529-09-5P 886529-11-9P 886529-18-6P
886529-19-7P 886529-20-0P 886529-21-1P
886529-44-8P 886529-45-9P 886529-63-1P
886529-64-2P 886530-11-6P 886535-99-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxylic acid derivs. containing thiazole moiety as PPARα agonists for treatment of hyperlipidemia and arteriosclerosis)

RN 886529-09-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 886529-11-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[methyl[5-[4-(trifluoromethoxy)phenyl]-2-

pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 886529-18-6 CAPLUS
CN Propanoic acid, 2-[[4-[2-[ethyl[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-2-methyl- (CA INDEX NAME)



RN 886529-19-7 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[(1-methylethyl)[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 886529-20-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[5-[4-(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 886529-21-1 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[5-[3-(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



RN 886529-44-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[5-[3-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 886529-45-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[methyl[5-[3-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 886529-63-1 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-methyl-5-[2-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



RN 886529-64-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-methyl-5-[2-[methyl[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, hydrochloride (1:?) (CA INDEX NAME)



RN 886530-11-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[2-[[4-[4-(trifluoromethoxy)phenyl]-2-

pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]-, hydrochloride (1:1) (CA INDEX NAME)



● x HCl

RN 886535-99-5 CAPLUS
CN Acetic acid, 2-[[4-[2-[[5-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]ethyl]-2-thiazolyl]thio]- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:340006 CAPLUS
DN 144:390933
TI Preparation of anilinopyrimidines as IKK kinase inhibitors
IN Sum, Fuk-Wah; Powell, Dennis William; Zhang, Yixian; Chen, Lijing; Kincaid, Scott Lee; Jennings, Lee Dalton; Hu, Yongbo; Gilbert, Adam Matthew; Bursavich, Matthew Gregory
PA Wyeth, John, and Brother Ltd., USA
SO U.S. Pat. Appl. Publ., 55 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20060079543	A1	20060413	US 2005-248495	20051013
	AU 2005295788	A1	20060427	AU 2005-295788	20051013
	CA 2580913	A1	20060427	CA 2005-2580913	20051013
	WO 2006044457	A1	20060427	WO 2005-US36674	20051013
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1799652	A1	20070627	EP 2005-812654	20051013
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	CN 101039919	A	20070919	CN 2005-80034935	20051013
	JP 2008515986	T	20080515	JP 2007-536838	20051013
	BR 2005016597	A	20080916	BR 2005-16597	20051013
	NO 2007001642	A	20070601	NO 2007-1642	20070328
	IN 2007DN02696	A	20070817	IN 2007-DN2696	20070411
	MX 2007004488	A	20070911	MX 2007-4488	20070413
	KR 2007084067	A	20070824	KR 2007-710445	20070508
PRAI	US 2004-617668P	P	20041013		
	WO 2005-US36674	W	20051013		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 144:390933; MARPAT 144:390933
AB Title compds. I [wherein R1, R4 = H; R2 = (un)substituted amino, guanidinyl, ureido, etc.; R3 = H, (un)substituted Ph, certain heteroaryl, etc.; R5 = H, alkyl, alkylsulfonyl, etc.; R6 = H, halo, (un)substituted Ph, etc.] and salts, solvates or hydrates thereof were prepared as kinase inhibitors, especially IKK kinase inhibitors. For instance, condensation of 2-acetyl-5-chlorothiophene with DMF di-Me acetal followed by cyclization with a guanidine, which was obtained by treatment of sulfanilamide with 1H-pyrazole-1-carboximidamide hydrochloride, gave 2-pyrimidinamine II. Exemplary I gave a pos. or slightly pos. result in the western anal. of IKKα. Therefore, I and their pharmaceutical compns. are useful for the treatment of diseases associated with NF-κB activation, such as inflammation, tumor and ischemic conditions.

IT 882874-45-5P 882874-49-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of anilinopyrimidines as IKK kinase inhibitors)
RN 882874-45-5 CAPLUS
CN Benzenesulfonamide, N-[3-(4-morpholinyl)propyl]-4-[[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 882874-49-9 CAPLUS
CN Benzenesulfonamide, N-[2-(4-morpholinyl)ethyl]-4-[[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L4 ANSWER 11 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1170507 CAPLUS
DN 143:440431
TI Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
IN Mjalli, Adnan M. M.; Gaddam, Bapu R.; Qabaja, Ghassan; Subramanian, Govindan; Zhu, Jeff; Dankwardt, John; Arimilli, Murty N.; Andrews, Robert C.; Victory, Samuel; Tian, Ye E.
PA Transtech Pharma, Inc., USA
SO PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005103022	A1	20051103	WO 2005-US13386	20050420
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2005236055	A1	20051103	AU 2005-236055	20050420
	CA 2562075	A1	20051103	CA 2005-2562075	20050420
	US 20050261294	A1	20051124	US 2005-110499	20050420
	EP 1753735	A1	20070221	EP 2005-757033	20050420
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1946703	A	20070411	CN 2005-80012513	20050420
	BR 2005010095	A	20071016	BR 2005-10095	20050420
	JP 2007533752	T	20071122	JP 2007-509585	20050420
	ZA 2006008225	A	20080130	ZA 2006-8225	20050420
	MX 2006012130	A	20070131	MX 2006-12130	20061020
	IN 2006KN03399	A	20070615	IN 2006-KN3399	20061116
PRAI	US 2004-563882P	P	20040420		
	WO 2005-US13386	W	20050420		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 143:440431; MARPAT 143:440431
AB Title compds. I [A = substituted amine, substituted alkyl, substituted sulfonamide, etc.; m = 0-2; R1 and R2 independently = H, halo, alkyl, etc., or R1 and R2 may be taken together to form part of a fused carbocyclic ring, aromatic ring, heteroarom. ring, etc.; W = S, N=N, or CR3=N; R3 = H, halo, alkyl, etc.], methods of their preparation, pharmaceutical compns. comprising the compds. of Formula (I), and methods of use in treating human or animal disorders are disclosed. Thus, e.g., II was prepared by cyclocondensation of 2-bromo-1(4-isopropylphenyl)ethanone (preparation given) with thiourea followed by reaction with chlorosulfonyl-acetic acid tert-Bu ester (preparation given). I showed an increase in cAMP production and a reduction in fluorescence polarization in assays

and possess an effective concentration for half maximal effect (EC50) in the assay of less than 14 μM. The compds. of the invention can be useful as inhibitors of action of AgRP on a melanocortin receptor and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.

IT 868590-78-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazole and pyrimidine derivs. as melanocortin receptor modulators)

RN 868590-78-7 CAPLUS

CN Benzoic acid, 2-[[(2-thienylmethyl)[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:1075803 CAPLUS
DN 143:367317
TI Preparation of N-(2-amino and 2-hydroxy)phenyl carboxamides as inhibitors of histone deacetylase
IN Delorme, Daniel; Vaisburg, Arkadii; Moradei, Oscar; Leit, Silvana; Raeppel, Stephane; Frechette, Sylvie; Bouchain, Giliane; Zhou, Zhihong; Paquin, Isabelle; Gaudette, Frederic; Isakovic, Ljubomir
PA Methylgene Inc., Can.
SO PCT Int. Appl., 245 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005092899	A1	20051006	WO 2005-CA454	20050329
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050245518	A1	20051103	US 2005-90713	20050325
	US 7253204	B2	20070807		
	AU 2005225471	A1	20051006	AU 2005-225471	20050329
	CA 2559733	A1	20051006	CA 2005-2559733	20050329
	EP 1735319	A1	20061227	EP 2005-714678	20050329
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	CN 1997649	A	20070711	CN 2005-80016112	20050329
	BR 2005009214	A	20070904	BR 2005-9214	20050329
	JP 2007530459	T	20071101	JP 2007-504228	20050329
	MX 2006010900	A	20070221	MX 2006-10900	20060922
	IN 2006KN03069	A	20070608	IN 2006-KN3069	20061023
	KR 2007022687	A	20070227	KR 2006-722299	20061026
	US 20070213330	A1	20070913	US 2007-687398	20070316
PRAI	US 2004-556828P	P	20040326		
	US 2005-90713	A	20050325		
	WO 2005-IB802	A	20050325		
	US 2004-90713	A	20040325		
	WO 2005-CA454	W	20050329		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 143:367317; MARPAT 143:367317
AB The invention relates to N-(2-amino and 2-hydroxy)phenyl carboxamides (2-TC6H4NHC(O)(CH:CH)qAr-X-Cy (I); variables defined below; e.g. (E)-N-(2-Aminophenyl)-3-[4-[[(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylamide (shown as II)) useful for inhibiting histone deacetylase (HDAC) enzymic activity. The invention also provides a method for inhibiting histone deacetylase in a cell using said compds. as well as a method for treating cell proliferative diseases

and conditions using said HDAC inhibitors. Further, the invention provides pharmaceutical compns. comprising the HDAC inhibiting compds. and a pharmaceutically acceptable carrier. For I: Cy is aryl, heteroaryl, cycloalkyl, or heterocyclyl, each of which is (un)substituted and each of which is optionally fused to ≥1 aryl or heteroaryl rings, or to ≥1 saturated or partially unsatd. cycloalkyl or heterocyclic rings, each of which rings is (un)substituted; X = a chemical bond, L, W-L, L-W, and L-W-L, wherein W, at each occurrence, is S, O, C:O, or N(R9), where R9 = H, alkyl, hydroxyalkyl, and tert-butoxycarbonyl; and L = C1-C4 alkylene; Ar is arylene or heteroarylene, each of which is (un)substituted; q = 0-1; and T is NH2 or OH, provided that when Cy is naphthyl, X is -CH2-, Ar is Ph, and q = 0-1, T is not OH. Although the methods of preparation are not claimed, 215 example prepns. and/or characterization data are included. For example, II was prepared in 6 steps (59, 83, 97, 79, 96 and 80 % yields) starting from (E)-4-formylcinnamic acid and involving intermediates Me (E)-3-(4-formylphenyl)acrylate, Me (E)-3-[4-[[[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylate, Me (E)-3-[4-[[[2-[(tert-butyldimethylsilanyl)oxy]ethyl][2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylate, (E)-3-[4-[[[2-[(tert-butyldimethylsilanyl)oxy]ethyl][2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylic acid and (E)-N-(2-aminophenyl)-3-[4-[[[2-[(tert-butyldimethylsilanyl)oxy]ethyl][2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]acrylamide.

IT 866000-05-7P, N-(2-Aminophenyl)-4-[[[4-(3-trifluoromethoxyphenyl)pyrimidin-2-yl]amino]methyl]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-(2-amino and 2-hydroxy)phenyl carboxamides as inhibitors of histone deacetylase)

RN 866000-05-7 CAPLUS

CN Benzamide, N-(2-aminophenyl)-4-[[[4-[3-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:395285 CAPLUS
DN 142:430294
TI Preparation of pyrimidine compounds as antistress agents
IN Ohmoto, Kazuyuki; Kato, Masashi; Katsumata, Seishi; Manako, Junichiro
PA Ono Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 133 pp.
CODEN: PIXXD2
Applicant's
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040135	A1	20050506	WO 2004-JP16056	20041022
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1679309	A1	20060712	EP 2004-793164	20041022
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, ~~EE, HU, PL, SK~~				
	US 20070099938	A1	20070503	US 2006-577047	20060901
PRAI	JP 2003-365237	A	20031024		
	WO 2004-JP16056	W	20041022		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 142:430294
AB Title compds. I [ring A = (un)substituted cyclic group; Q = (un)substituted alkyl; (un)substituted cyclic group; ring D = (un)substituted cyclic group; W = bond, spacer with a principal chain of 1 to 4 atoms; Y = spacer with a principal chain of 1 to 4 atoms] were prepared For example, benzyloxyacetylation of 4-phenyl-2-aminopyrimidine, e.g., prepared from acetophenone in 2 steps, afforded compound II. In MBR (mitochondrial benzodiazepine receptor) binding assays, the Ki value of compound III was 0.01 μmol/L. Compoounds I are claimed useful for the treatment of depression, asthma etc. Formulations are given.
IT 850924-82-2P 850924-86-6P 850925-10-9P
850925-22-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of pyrimidine compds. for treatment of depression, asthma etc.)
RN 850924-82-2 CAPLUS
CN Methanesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 850924-86-6 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 850925-10-9 CAPLUS
CN Acetamide, N-[4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 850925-22-3 CAPLUS
CN Acetamide, N-[4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]-N-ethyl- (CA INDEX NAME)



IT 850924-46-8P 850924-47-9P 850924-51-5P

850924-77-5P 850924-79-7P 850924-80-0P
850924-81-1P 850924-83-3P 850924-84-4P
850924-85-5P 850924-87-7P 850924-88-8P
850925-04-1P 850925-06-3P 850925-07-4P
850925-08-5P 850925-09-6P 850925-11-0P
850925-14-3P 850925-15-4P 850925-16-5P
850925-17-6P 850925-18-7P 850925-19-8P
850925-20-1P 850925-21-2P 850925-24-5P
850925-25-6P 850925-27-8P 850925-29-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine compds. for treatment of depression, asthma etc.)

RN 850924-46-8 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 850924-47-9 CAPLUS
CN Benzamide, N-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 850924-51-5 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 850924-77-5 CAPLUS
CN Acetamide, 2-phenoxy-N-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]-

(CA INDEX NAME)



RN 850924-79-7 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-5-chloro- (CA INDEX NAME)



RN 850924-80-0 CAPLUS
CN Urea, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N'-phenyl- (CA INDEX NAME)



RN 850924-81-1 CAPLUS
CN Urea, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N'-(1-methylethyl)- (CA INDEX NAME)



RN 850924-83-3 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 850924-84-4 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-4-methyl- (CA INDEX NAME)



RN 850924-85-5 CAPLUS
CN Benzenemethanesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 850924-87-7 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]-4-methyl- (CA INDEX NAME)



RN 850924-88-8 CAPLUS
CN Methanesulfonamide, N-[4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 850925-04-1 CAPLUS
CN Benzenemethanesulfonamide, N-[4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 850925-06-3 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-3-methyl- (CA INDEX NAME)



RN 850925-07-4 CAPLUS

CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-3,5-dimethyl- (CA INDEX NAME)



RN 850925-08-5 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-3,5-dichloro- (CA INDEX NAME)



RN 850925-09-6 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-4-(methylsulfonyl)- (CA INDEX NAME)



RN 850925-11-0 CAPLUS
CN Methanesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 850925-14-3 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N-ethyl- (CA INDEX NAME)



RN 850925-15-4 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N-propyl- (CA INDEX NAME)



RN 850925-16-5 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N-(2-methylpropyl)- (CA INDEX NAME)



RN 850925-17-6 CAPLUS

CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 850925-18-7 CAPLUS
CN 2-Pyrimidinamine, 4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-N-ethyl- (CA INDEX NAME)



RN 850925-19-8 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]-N-methyl- (CA INDEX NAME)



RN 850925-20-1 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]-N,4-dimethyl- (CA INDEX NAME)



RN 850925-21-2 CAPLUS
CN Benzenesulfonamide, N-[4-[2,5-bis(difluoromethoxy)phenyl]-2-pyrimidinyl]-N-methyl- (CA INDEX NAME)



RN 850925-24-5 CAPLUS
CN 2-Pyrimidinamine, 4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-N-methyl-N-(phenylmethyl)- (CA INDEX NAME)



RN 850925-25-6 CAPLUS
CN 2-Pyrimidinamine, 4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-N-(phenylmethyl)- (CA INDEX NAME)



RN 850925-27-8 CAPLUS

CN 2-Pyrimidinamine, 4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-N,N-diethyl- (CA INDEX NAME)



RN 850925-29-0 CAPLUS
CN 1-Pentanol, 5-[[4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



IT 850925-34-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine compds. for treatment of depression, asthma etc.)
RN 850925-34-7 CAPLUS
CN Pentanamide, N-[4-[2,5-bis(2,2,2-trifluoroethoxy)phenyl]-2-pyrimidinyl]-5-bromo- (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 116 THERE ARE 116 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:123194 CAPLUS
DN 142:219265
TI Preparation of novel spiro compounds as neuropeptide Y antagonists
IN Fukami, Takehiro; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Takahashi, Toshiyuki; Haga, Yuji; Sakamoto, Toshihiro; Itoh, Takahiro; Chiba, Masato
PA Banyu Pharmaceutical Co., Ltd., Japan
SO U.S. Pat. Appl. Publ., 32 pp., Cont.-in-part of Appl. No. PCT/JP03/02611.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050032820	A1	20050210	US 2004-922869	20040823
	US 7304072	B2	20071204		
	US 20020188124	A1	20021212	US 2002-92549	20020308
	US 6803372	B2	20041012		
	WO 2003076443	A1	20030918	WO 2003-JP2611	20030305
	WO 2003076443	A9	20050120		
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GH, HR, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, RU, SC, SG, TJ, TM, TN, TT, UA, US, UZ, VC, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-92549	A2	20020308		
	WO 2003-JP2611	A2	20030305		
	JP 1999-233573	A	19990820		
	JP 2000-137692	A	20000510		
	US 2000-640784	A3	20000818		
	US 2001-983598	A2	20011025		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 142:219265; MARPAT 142:219265
AB Spiro compds. represented by the general formula (I) (wherein Ar1, Ar2 = each (un)substituted aryl or heteroaryl; n = 0 or 1; T, U, V, W = each independently N atom or CH group which may have a substituent selected from the group consisting of halogen, lower alkyl, hydroxy, and lower alkoxy, wherein at least two of which represent said methine group; X = hydroxy substituted methine or nitrogen atom; Y = an imino which may be substituted with lower alkyl, or oxygen), salts, esters, or N-oxide derivs. thereof are prepared These compds. exhibit neuropeptide Y (NPY) antagonistic activities and are useful as agents for the treatment of various diseases related to NPY, for example, (1) cardiovascular disorders such as hypertension, nephropathy, heart disease, vasospasm, and arteriosclerosis, (2) central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, and drug withdrawal, (3) metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, and hyperlipidemia, (4) sexual and reproductive dysfunction, gastro-intestinal disorder, respiratory disorder, inflammation or glaucoma. Thus, 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (400 mg) was added to a mixture of trans-3-oxospiro(6-azaisobenzofuran-1(3H),1'-cyclohexane)-4'-carboxylic acid (436 mg) and

3-amino-1-(4-benzyloxy-2-fluorophenyl)pyrazole (500 mg) in pyridine (10 mL), and the mixture was stirred overnight to give, after workup, 783.7 mg trans-N-[1-(4-benzyloxy-2-fluorophenyl)-3-pyrazolyl]-3-oxospiro(6-azaisobenzofuran-1(3H),1'-cyclohexane)-4'-carboxamide (II). A mixture of 783.7 mg II and 100 mg 10% Pd-C in THF was stirred under hydrogen atmospheric at
room temperature for 24 h to give, after silica gel chromatog. and recrystn. from EtOAc, 531.7 mg trans-N-[1-(2-fluoro-4-hydroxyphenyl)-3-pyrazolyl]-3-oxospiro(6-azaisobenzofuran-1(3H),1'-cyclohexane)-4'-carboxamide (III). III in vitro inhibited the binding of [125I]peptide YY to a membrane sample prepared from cells which expressed human neuropeptide Y Y5 receptor with IC50 of 3.0 nM.

IT 478013-33-1P 478013-34-2P 478013-35-3P
478013-60-4P 478013-61-5P 478013-62-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel spiro compds. as neuropeptide Y antagonists for treating cardiovascular disorders, central nervous system disorders, and metabolic diseases, etc.)

RN 478013-33-1 CAPLUS
CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-4-hydroxy-3'-oxo-, (1α,4α)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-34-2 CAPLUS
CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-3'-oxo-, 5'-oxide, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-35-3 CAPLUS
CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-4-hydroxy-3'-oxo-, 5'-oxide, (1α,4α)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-60-4 CAPLUS
CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-4-hydroxy-1'-oxo-, (1α,4α)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-61-5 CAPLUS
CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-1'-oxo-, 5'-oxide, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-62-6 CAPLUS
CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-4-hydroxy-1'-oxo-, 5'-oxide, (1α,4α)- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:14148 CAPLUS
DN 142:107413
TI Combination therapy for the treatment of dyslipidemia
IN Erondu, Ngozi E.; Fong, Tung M.; MacNeil, Douglas J.; Van Der Ploeg, Leonardus H. T.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

same as #17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005000217	A2	20050106	WO 2004-US17120	20040602
	WO 2005000217	A3	20050407		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1635813	A2	20060322	EP 2004-753858	20040602
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20060148721	A1	20060706	US 2005-555194	20051101
PRAI	US 2003-476387P	P	20030606		
	WO 2004-US17120	W	20040602		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 142:107413
AB The invention relates to compns. comprising an anti-obesity agent and an anti-dyslipidemic agent useful for the treatment of dyslipidemia, dyslipidemia associated with obesity and dyslipidemia-related disorders. The invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The invention further provides pharmaceutical compns., medicaments, and kits useful in carrying out these methods.
IT 328232-69-5 328232-78-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy for treatment of dyslipidemia)
RN 328232-69-5 CAPLUS
CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-3'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 328232-78-6 CAPLUS
CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-1'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:1124587 CAPLUS
DN 142:69188
TI Combination therapy for the treatment of diabetes
IN Erondu, Ngozi E.; Fong, Tung M.; MacNeil, Douglas J.; Van Der Ploeg, Leonardus H. T.; Kanatani, Akio
PA Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.
SO PCT Int. Appl., 109 pp.
CODEN: PIXXD2
same as #17
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110375	A2	20041223	WO 2004-US17291	20040602
	WO 2004110375	A3	20050512		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1635832	A2	20060322	EP 2004-753999	20040602
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20070099884	A1	20070503	US 2005-559206	20051202
PRAI	US 2003-476388P	P	20030606		
	WO 2004-US17291	W	20040602		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 142:69188
AB The present invention relates to compns. comprising an anti-obesity agent and an anti-diabetic agent useful for the treatment of diabetes, diabetes associated with obesity and diabetes-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compns., medicaments, and kits useful in carrying out these methods.
IT 328232-69-5 328232-78-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuropeptide Y Y5 receptor antagonist; combination therapy of diabetes and diabetes-related disorders using antiobesity agent and antidiabetic agent and other agents)
RN 328232-69-5 CAPLUS
CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-3'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 328232-78-6 CAPLUS
CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-1'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:1124581 CAPLUS
DN 142:69181
TI Combination therapy for the treatment of hypertension
IN Fong, Tung M.; Erondu, Ngozi E.; Macneil, Douglas J.; Mcintyre, James H.; Van Der Ploeg, Leonardus H. T.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English

same as # 19

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004110368	A2	20041223	WO 2004-US17090	20040602
	WO 2004110368	A3	20060720		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1635773	A2	20060322	EP 2004-753832	20040602
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 20060160834	A1	20060720	US 2005-559111	20051202
PRAI	US 2003-476390P	P	20030606		
	WO 2004-US17090	W	20040602		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 142:69181
AB The present invention relates to compns. comprising an anti-obesity agent and an anti-hypertensive agent useful for the treatment of hypertension, hypertension associated with obesity, and hypertension-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compns., medicaments, and kits useful in carrying out these methods.
IT 328232-69-5 328232-78-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neuropeptide Y Y5 receptor antagonist; combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents)
RN 328232-69-5 CAPLUS
CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-3'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 328232-78-6 CAPLUS
CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-1'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:451634 CAPLUS
DN 141:23544
TI Preparation of anilinopyrimidines as JNK pathway inhibitors for treating or preventing an inflammatory or metabolic condition
IN Satoh, Yoshitaka; Bhagwat, Shripad S.
PA Signal Pharmaceuticals, LLC, USA
SO U.S. Pat. Appl. Publ., 161 pp., Cont.-in-part of U.S. Ser. No. 4,645.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20040106634	A1	20040603	US 2003-395811	20030324
	US 7429599	B2	20080930		
	US 20030220330	A1	20031127	US 2001-4645	20011204
	US 7129242	B2	20061031		
	AU 2004224302	A1	20041007	AU 2004-224302	20040324
	CA 2520440	A1	20041007	CA 2004-2520440	20040324
	WO 2004084901	A1	20041007	WO 2004-US9208	20040324
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1608375	A1	20051228	EP 2004-758138	20040324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
	BR 2004008784	A	20060328	BR 2004-8784	20040324
	CN 1791410	A	20060621	CN 2004-80013588	20040324
	JP 2006521394	T	20060921	JP 2006-509310	20040324
	ZA 2005007987	A	20071227	ZA 2005-7987	20040324
	NZ 543052	A	20090131	NZ 2004-543052	20040324
PRAI	US 2000-251904P	P	20001206		
	US 2001-4645	A2	20011204		
	US 2003-395811	A	20030324		
	WO 2004-US9208	W	20040324		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 141:23544
AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2, R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of ≤ 10 μM in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition (such as obesity).
IT 434945-02-5P 434945-17-2P 434945-32-1P
434945-38-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anilinopyrimidines as JNK pathway inhibitors for treating or preventing an inflammatory or metabolic condition)

RN 434945-02-5 CAPLUS
CN Benzamide, 4-[[4-[4-[(trifluoromethyl)thio]phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 434945-17-2 CAPLUS
CN Benzamide, 4-[[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 434945-32-1 CAPLUS
CN Ethanone, 1-[4-[4-[[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 434945-38-7 CAPLUS
CN Ethanone, 1-[4-[4-[[4-[4-[(trifluoromethyl)thio]phenyl]-2-pyrimidinyl]amino]benzoyl]-1-piperazinyl]- (CA INDEX NAME)



OSC.G 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2004:80448 CAPLUS
DN 140:122817
TI NPY5 antagonist-antiobesity agent combination for the prevention and treatment of diabetes, obesity, and obesity-related disorders
IN Macneil, Douglas J.; Mcintyre, James H.; Van Der Ploeg, Leonardus H. T.; Ishihara, Akane
PA Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.
SO PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DT Patent
LA English

same as # 20

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004009015	A2	20040129	WO 2003-US22077	20030714
	WO 2004009015	A3	20040304		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2492225	A1	20040129	CA 2003-2492225	20030714
	AU 2003253925	A1	20040209	AU 2003-253925	20030714
	EP 1534074	A2	20050601	EP 2003-765587	20030714
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005533849	T	20051110	JP 2004-523149	20030714
	US 20050288213	A1	20051229	US 2005-520566	20050107
PRAI	US 2002-396603P	P	20020718		
	US 2002-417999P	P	20021011		
	WO 2003-US22077	W	20030714		

OS MARPAT 140:122817
AB The invention discloses compns. comprising a NPY5 antagonist and an antiobesity agent, useful for the treatment and prevention of diabetes, obesity, and obesity-related disorders. The invention also discloses methods of treating or preventing obesity and obesity-related disorders in a subject in need thereof by administering a composition of the invention. The invention further discloses pharmaceutical compns., medicaments, and kits useful in carrying out the methods.
IT 328232-69-5 328232-78-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(NPY5 antagonist-antiobesity agent combination for the prevention and treatment of diabetes, obesity, and obesity-related disorders)
RN 328232-69-5 CAPLUS
CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-3'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 328232-78-6 CAPLUS
CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-1'-oxo-, (1α,4β)-
(CA INDEX NAME)

Relative stereochemistry.



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:947029 CAPLUS
DN 138:24705
TI Preparation of spiroisoindolinepiperidinecarboxamides, spirocyclohexaneisobenzofurancarboxamides, spiroazaisobenzofurancyclohexanecarboxamides, and related compounds as neuropeptide Y antagonists.
IN Fukami, Takehiro; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Takahashi, Toshiyuki; Haga, Yuji; Sakamoto, Toshihiro; Itoh, Takahiro
PA Banyu Pharmaceutical Co., Ltd., Japan
SO U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Pat. Appl. 2002 52,371.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020188124	A1	20021212	US 2002-92549	20020308
	US 6803372	B2	20041012		
	US 6326375	B1	20011204	US 2000-640784	20000818
	US 6335345	B1	20020101	US 2001-928431	20010814
	US 20020052371	A1	20020502	US 2001-983598	20011025
	US 6388077	B2	20020514		
	ZA 2002000734	A	20030128	ZA 2002-734	20020128
	US 6462053	B2	20021008	US 2002-101221	20020320
	US 20020165391	A1	20021107		
	US 20030055251	A1	20030320	US 2002-226225	20020823
	US 6649624	B2	20031118		
	JP 2003104884	A	20030409	JP 2002-271261	20020918
	JP 3553560	B2	20040811		
	CA 2482191	A1	20030918	CA 2003-2482191	20030305
	WO 2003076443	A1	20030918	WO 2003-JP2611	20030305
	WO 2003076443	A9	20050120		
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GH, HR, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, RU, SC, SG, TJ, TM, TN, TT, UA, US, UZ, VC, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003221319	A1	20030922	AU 2003-221319	20030305
	EP 1483266	A1	20041208	EP 2003-710252	20030305
	EP 1483266	B1	20080227		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005519955	T	20050707	JP 2003-574660	20030305
	AT 387452	T	20080315	AT 2003-710252	20030305
	US 20030220499	A1	20031127	US 2003-453737	20030604
	US 6723847	B2	20040420		
	US 20050032820	A1	20050210	US 2004-922869	20040823
	US 7304072	B2	20071204		
PRAI	JP 1999-233573	A	19990820		
	JP 2000-137692	A	20000510		
	US 2000-640784	A3	20000818		
	US 2001-983598	A2	20011025		

JP 2000-247145 A3 20000817
US 2002-92549 A 20020308
US 2002-101221 A3 20020320
US 2002-226225 A3 20020823
WO 2003-JP2611 W 20030305

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 138:24705

AB Title compds. [I; Ar1 = (substituted) aryl, heteroaryl, QAr2; Ar2 = (substituted) aryl, heteroaryl; Q = bond, CO; T, U, V, W = N, (substituted) CH; X = CH, CH(OH); Y = (substituted) imino, O], were prepared Thus, N-tert-butoxycarbonyl-4-piperidone was refluxed 3 h with PhCH2NH2 in PhMe to give a residue which was stirred with o-iodobenzoyl chloride and Et3N in PhMe at 80° for 2 h to give N-benzyl-N-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-iodobenzamide. The latter was heated with Pd(OAc)2, Ph3P, K2CO3, and Et4NCl in MeCN at 80° for 6 h to give 2-benzyl-1'-tert-butoxycarbonyl-1',6'-dihydrospiro[1H-isoindole-1,4'(5'H)-pyridine]-3(2H)-one. This was converted to N-(4-benzoylphenyl)-3-oxospiro[isoindoline-1,4'-piperidine]-1'-carboxamide (II), which inhibited [125I]neuropeptide Y binding to NPY Y5 receptors with IC50 = 1.2 nM. II drug formulations are given.

IT 328232-69-5P 328232-78-6P 478013-33-1P
478013-34-2P 478013-35-3P 478013-60-4P
478013-61-5P 478013-62-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiroisoindolinepiperidinecarboxamides, spirocyclohexaneisobenzofurancarboxamides, spiroazaisobenzofurancyclohexanecarboxamides, and related compds. as neuropeptide Y antagonists)

RN 328232-69-5 CAPLUS

CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-3'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 328232-78-6 CAPLUS

CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-1'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-33-1 CAPLUS
CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-4-hydroxy-3'-oxo-, (1α,4α)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-34-2 CAPLUS
CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-3'-oxo-, 5'-oxide, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-35-3 CAPLUS
CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-4-hydroxy-3'-oxo-, 5'-oxide, (1α,4α)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-60-4 CAPLUS
CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-4-hydroxy-1'-oxo-, (1α,4α)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-61-5 CAPLUS
CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-1'-oxo-, 5'-oxide, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 478013-62-6 CAPLUS
CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-4-hydroxy-1'-oxo-, 5'-oxide, (1α,4α)- (CA INDEX NAME)

Relative stereochemistry.



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:814853 CAPLUS
DN 137:325431
TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manjo; Levine, Barry H.
PA USA
SO U.S. Pat. Appl. Publ., 134 pp., Cont.-in-part of U.S. 6,417,185.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20020156087	A1	20021024	US 2001-949035	20010906
	US 7045519	B2	20060516		
	US 6417185	B1	20020709	US 1999-336038	19990618
	US 20030130289	A1	20030710	US 2002-309535	20021203
	US 7037918	B2	20060502		
	US 20060089369	A1	20060427	US 2005-220400	20050906
	US 7425557	B2	20080916		
PRAI	US 1998-89978P	P	19980619		
	US 1999-336038	A2	19990618		
	US 2000-230480P	P	20000906		
	US 1999-336098	A3	19990618		
	US 2001-949035	A3	20010906		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 137:325431
AB Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidinyl, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO2, (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidinyl, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3β in a cell free assay with IC50 values of < 1 μM. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, or cancer (no data).
IT 252905-23-0P, 5-Pyrimidinecarboxylic acid, 2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-[4-(trifluoromethoxy)phenyl]-, ethyl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)

RN 252905-23-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-[4-(trifluoromethoxy)phenyl]-, ethyl ester (CA INDEX NAME)



IT 403807-25-0, [2-(2-Pyridylamino)ethyl][4-[4-(trifluoromethoxy)phenyl]pyrimidin-2-yl]amine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)

RN 403807-25-0 CAPLUS

CN 1,2-Ethanediamine, N1-2-pyridinyl-N2-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT 306 THERE ARE 306 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:449662 CAPLUS
DN 137:33310
TI Preparation of anilinopyrimidines as IKK inhibitors
IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PA Signal Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 194 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046171	A2	20020613	WO 2001-US46403	20011205
	WO 2002046171	A3	20030123		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20030203926	A1	20031030	US 2001-4642	20011204
	US 7122544	B2	20061017		
	CA 2431160	A1	20020613	CA 2001-2431160	20011205
	AU 2002020195	A	20020618	AU 2002-20195	20011205
	EP 1349841	A2	20031008	EP 2001-999564	20011205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004523497	T	20040805	JP 2002-547910	20011205
	AU 2002220195	B2	20060824	AU 2002-220195	20011205
	US 20060030576	A1	20060209	US 2005-211383	20050824
	US 7442699	B2	20081028		
PRAI	US 2000-251816P	P	20001206		
	US 2001-4642	A1	20011204		
	WO 2001-US46403	W	20011205		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 137:33310
AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of IKK, particularly IKK-2, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of ≤ 1 μM in the IKK-2 enzyme assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds.
IT 434945-02-5P 434945-17-2P 434945-32-1P
434945-38-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anilinopyrimidines as IKK inhibitors)

RN 434945-02-5 CAPLUS
CN Benzamide, 4-[[4-[4-[(trifluoromethyl)thio]phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 434945-17-2 CAPLUS
CN Benzamide, 4-[[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 434945-32-1 CAPLUS
CN Ethanone, 1-[4-[4-[[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 434945-38-7 CAPLUS
CN Ethanone, 1-[4-[4-[[4-[4-[(trifluoromethyl)thio]phenyl]-2-pyrimidinyl]amino]benzoyl]-1-piperazinyl]- (CA INDEX NAME)



OSC.G 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:449661 CAPLUS
DN 137:33309
TI Preparation of anilinopyrimidines as JNK pathway inhibitors
IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PA Signal Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046170	A2	20020613	WO 2001-US46402	20011205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2430966	A1	20020613	CA 2001-2430966	20011205
	AU 2002027214	A	20020618	AU 2002-27214	20011205
	EP 1349840	A2	20031008	EP 2001-996103	20011205
	EP 1349840	B1	20090311		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004534728	T	20041118	JP 2002-547909	20011205
	AU 2002227214	B2	20061123	AU 2002-227214	20011205
	AT 425149	T	20090315	AT 2001-996103	20011205
PRAI	US 2000-251904P	P	20001206		
	WO 2001-US46402	W	20011205		

OS MARPAT 137:33309
AB The title compds. [I; R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)aCOR9, (CH2)aCO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; a = 0-4] having activity as inhibitors of the JNK pathway, were prepared E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of ≤ 10 μM in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. containing one or more compds. of the above compds.
IT 434945-02-5P 434945-17-2P 434945-32-1P
434945-38-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anilinopyrimidines as JNK pathway inhibitors)
RN 434945-02-5 CAPLUS
CN Benzamide, 4-[[4-[4-[(trifluoromethyl)thio]phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 434945-17-2 CAPLUS
CN Benzamide, 4-[[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 434945-32-1 CAPLUS
CN Ethanone, 1-[4-[4-[[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]amino]benzoyl]-1-piperazinyl]- (CA INDEX NAME)



RN 434945-38-7 CAPLUS
CN Ethanone, 1-[4-[4-[[4-[4-[(trifluoromethyl)thio]phenyl]-2-pyrimidinyl]amino]benzoyl]-1-piperazinyl]- (CA INDEX NAME)



OSC.G 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

L4 ANSWER 24 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2002:185092 CAPLUS
DN 136:247598
TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manoj; Levine, Barry H.
PA Chiron Corporation, USA
SO PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020495	A2	20020314	WO 2001-US42081	20010906
	WO 2002020495	A3	20020620		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001095026	A	20020322	AU 2001-95026	20010906
	EP 1317433	A2	20030611	EP 2001-975734	20010906
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004514656	T	20040520	JP 2002-525117	20010906
	CN 1592743	A	20050309	CN 2001-818425	20010906
	AU 2001295026	B2	20080403	AU 2001-295026	20010906
	IN 2003KN00277	A	20050311	IN 2003-KN277	20030305
	KR 816769	B1	20080326	KR 2003-703327	20030306
	KR 2008013026	A	20080212	KR 2008-701887	20080124
	KR 860827	B1	20080930		
PRAI	US 2000-230480P	P	20000906		
	WO 2001-US42081	W	20010906		
	KR 2003-703327	A3	20030306		

OS MARPAT 136:247598
AB Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidinyl, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO2, (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidinyl, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to afford, after resin cleavage,

the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3β in a cell free assay with IC50 values of < 1 μM. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, or cancer (no data).

IT 252905-23-0P, 5-Pyrimidinecarboxylic acid, 2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-[4-(trifluoromethoxy)phenyl]-, ethyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)

RN 252905-23-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-[4-(trifluoromethoxy)phenyl]-, ethyl ester (CA INDEX NAME)



IT 403807-25-0, [2-(2-Pyridylamino)ethyl][4-[4-(trifluoromethoxy)phenyl]pyrimidin-2-yl]amine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)

RN 403807-25-0 CAPLUS

CN 1,2-Ethanediamine, N1-2-pyridinyl-N2-[4-[4-(trifluoromethoxy)phenyl]-2-pyrimidinyl]- (CA INDEX NAME)



OSC.G 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2001:152682 CAPLUS
DN 134:207809
TI Preparation of spiroisoindolinepiperidines, spiroisoquinolinepiperidines, spiroisobenzofuranpiperidines, and related compounds as neuropeptide Y antagonists.
IN Fukami, Takehiro; Kanatani, Akio; Ishihara, Akane; Ishii, Yasuyuki; Takahashi, Toshiyuki; Haga, Yuji; Sakamoto, Toshihiro; Itoh, Takahiro
PA Banyu Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 164 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

same as # 20

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001014376	A1	20010301	WO 2000-JP5427	20000811
	W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	TW 279402	B	20070421	TW 2000-89115560	20000803
	CA 2379103	A1	20010301	CA 2000-2379103	20000811
	BR 2000013423	A	20020507	BR 2000-13423	20000811
	EP 1204663	A1	20020515	EP 2000-951971	20000811
	EP 1204663	B1	20031029		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	TR 200200408	T2	20020621	TR 2002-408	20000811
	HU 2002003107	A2	20021228	HU 2002-3107	20000811
	HU 2002003107	A3	20040628		
	EE 200200082	A	20030616	EE 2002-82	20000811
	NZ 517057	A	20030829	NZ 2000-517057	20000811
	AU 767229	B2	20031106	AU 2000-64762	20000811
	AT 253064	T	20031115	AT 2000-951971	20000811
	ES 2206287	T3	20040516	ES 2000-951971	20000811
	CN 1202108	C	20050518	CN 2000-811855	20000811
	CN 1640877	A	20050720	CN 2004-10083535	20000811
	CN 100457757	C	20090204		
	IL 148119	A	20080106	IL 2000-148119	20000811
	SK 286609	B6	20090205	SK 2002-252	20000811
	JP 2002030086	A	20020129	JP 2000-247145	20000817
	JP 3411262	B2	20030526		
	IN 2002KN00125	A	20050311	IN 2002-KN125	20020125
	ZA 2002000734	A	20030128	ZA 2002-734	20020128
	HR 2002000102	B1	20050430	HR 2002-102	20020201
	BG 106390	A	20021229	BG 2002-106390	20020206
	MX 2002001693	A	20020806	MX 2002-1693	20020218
	NO 2002000814	A	20020415	NO 2002-814	20020219
	NO 323514	B1	20070604		
	KR 749713	B1	20070816	KR 2002-702202	20020220
	HK 1043123	A1	20040130	HK 2002-104686	20020624
	US 20030055251	A1	20030320	US 2002-226225	20020823
	US 6649624	B2	20031118		

	JP 2003104884	A	20030409	JP 2002-271261	20020918
	JP 3553560	B2	20040811		
	US 20030220499	A1	20031127	US 2003-453737	20030604
	US 6723847	B2	20040420		
PRAI	JP 1999-233573	A	19990820		
	JP 2000-137692	A	20000510		
	WO 2000-JP5427	W	20000811		
	JP 2000-247145	A3	20000817		
	US 2000-640784	A3	20000818		
	US 2001-983598	A3	20011025		
	US 2002-101221	A3	20020320		
	US 2002-226225	A3	20020823		

OS MARPAT 134:207809

AB Title compds. [I; Ar1 = (substituted) aryl, heteroaryl, QAr2; Ar2 = (substituted) aryl, heteroaryl; Q = bond, CO; T, U, V, W = N, (substituted) CH; X = N, CH; Y = (substituted) imino], were prepared Thus, N-tert-butoxycarbonyl-4-piperidone was refluxed 3 h with PhCH2NH2 in PhMe to give a residue which was stirred with o-iodobenzoyl chloride and Et3N in PhMe at 80° for 2 h to give N-benzyl-N-(1-tert-butoxycarbonyl-1,2,3,6-tetrahydropyridin-4-yl)-2-iodobenzamide. The latter was heated with Pd(OAc)2, Ph3P, K2CO3, and Et4NCl in MeCN at 80° for 6 h to give 2-benzyl-1'-tert-butoxycarbonyl-1',6'-dihydrospiro[1H-isoindole-1,4'(5'H)-pyridine]-3(2H)-one. This was converted to N-(4-benzoylphenyl)-3-oxospiro[isoindoline-1,4'-piperidine]-1'-carboxamide, (II), which inhibited [125I]peptide YY binding to NPY Y5 receptors with IC50 = 1.2 nM. II drug formulations are given.

IT 328232-69-5P 328232-78-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of spiroisoindolinepiperidines, spiroisoquinolinepiperidines, spiroisobenzofuranpiperidines, and related compds. as neuropeptide Y antagonists)

RN 328232-69-5 CAPLUS

CN Spiro[cyclohexane-1,1'(3'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-3'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



RN 328232-78-6 CAPLUS

CN Spiro[cyclohexane-1,3'(1'H)-furo[3,4-c]pyridine]-4-carboxamide, N-[5-[3-(fluoromethoxy)phenyl]-2-pyrimidinyl]-1'-oxo-, (1α,4β)- (CA INDEX NAME)

Relative stereochemistry.



OSC.G 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (36 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1999:811233 CAPLUS
DN 132:64265
TI Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
IN Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Brown, Sean P.; Goff, Dane; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithry; Renhowe, Paul A.; Seely, Lynn; Subramanian, Sharadha; Wagman, Allan S.; Zhou, Xiaohui A.
PA Chiron Corporation, USA
SO PCT Int. Appl., 262 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9965897	A1	19991223	WO 1999-US13809	19990618
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9949566	A	20000105	AU 1999-49566	19990618
	EP 1087963	A1	20010404	EP 1999-933522	19990618
	EP 1087963	B1	20040825		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6489344	B1	20021203	US 1999-336098	19990618
	JP 2003527303	T	20030916	JP 2000-554722	19990618
	AT 274510	T	20040915	AT 1999-933522	19990618
	IN 2000KN00609	A	20050311	IN 2000-KN609	20001207
	US 20030130289	A1	20030710	US 2002-309535	20021203
	US 7037918	B2	20060502		
PRAI	US 1998-89978P	P	19980619		
	US 1999-336098	A3	19990618		
	WO 1999-US13809	W	19990618		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 132:64265
AB RZCR2R12CR3R13Z1R5 [I; R = (un)substituted (hetero)aryl; Z = O, NR1, CR1R11; Z1 = O, NR4, CR4R14; R1-R4 = H, OH, NH2, alkyl, alkoxy, etc.; R5 = (un)substituted 2-pyridyl or -pyrimidyl; R11-R14 = H or alkyl] were prepared Thus, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine which was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to give, after resin cleavage, title compound II. Data for biol. activity of I were given.
IT 252905-23-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors)
RN 252905-23-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 2-[[2-[(5-nitro-2-pyridinyl)amino]ethyl]amino]-4-[4-(trifluoromethoxy)phenyl]-, ethyl ester (CA INDEX NAME)



OSC.G 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 27 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1995:909361 CAPLUS
DN 123:313996
OREF 123:56291a,56294a
TI Preparation of N-phenyl-2-pyrimidineamine antitumor agents
IN Zimmermann, Juerg
PA Ciba-Geigy A.-G., Switz.
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9509847	A1	19950413	WO 1994-EP3150	19940921
	W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2148931	A1	19950413	CA 1993-2148931	19930921
	AU 9476976	A	19950501	AU 1994-76976	19940921
	AU 693475	B2	19980702		
	EP 672035	A1	19950920	EP 1994-927634	19940921
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08503971	T	19960430	JP 1994-510577	19940921
	US 5612340	A	19970318	US 1995-436345	19950517
PRAI	CH 1993-2967	A	19931001		
	CH 1994-2279	A	19940718		
	WO 1994-EP3150	W	19940921		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS MARPAT 123:313996
AB N-phenyl-2-pyrimidineamine derivs. [I; R1 = naphthyl, fluorenyl, anthracenyl, (un)substituted cyclic residue, etc.; R2 = NO2, F-substituted lower alkoxy, etc.] [e.g., N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-(3,4,5-trimethoxyphenyl)-2-pyrimidineamine; m.p. 132°], useful for the treatment of tumor diseases (no data), are prepared and I-containing formulations presented.
IT 170140-92-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenyl-2-pyrimidineamine antitumor agents)
RN 170140-92-8 CAPLUS
CN 2-Pyrimidinamine, N-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-4-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)



OSC.G 43 THERE ARE 43 CAPLUS RECORDS THAT CITE THIS RECORD (45 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                  ENTRY     SESSION
FULL ESTIMATED COST                               153.28      342.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                  ENTRY     SESSION
CA SUBSCRIBER PRICE                               -22.14      -22.14

STN INTERNATIONAL LOGOFF AT 11:27:29 ON 31 AUG 2009
```